drugset
drugset / Trial / NCT06782932

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

NCT06782932 ↗

Phase 1/2 Recruiting 38 enrolled Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Agenus Inc. · collabLustgarten Foundation · collabOncovir, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the optimal dose of AGEN2373 that is safe when given in combination with balstilimab and Pancreatic GVAX Whole Cell Vaccine and evaluate the safety and clinical activity of balstilimab and AGEN2373 in combination with GVAX (Arm 1) or mKRASvax (Arm 2) in surgically resectable pancreatic adenocarcinoma.

Timeline

Start
2025-05-27
Primary completion
2028-12
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Subject AGEN2373 Unknown 1 mg/kg Intravenous
Subject AGEN2373 Unknown 3 mg/kg Intravenous
Subject AGEN2373 Unknown 10 mg/kg Intravenous
Subject GVAX Vaccine 5e+08 cells Other
Subject mKRASvax Unknown 0.3 mg Subcutaneous
Background Balstilimab Monoclonal antibody 450 mg Intravenous
Background Cyclophosphamide Other / unclassified 200 mg/m2 Intravenous
Background Hiltonol Other / unclassified 0.5 mg Subcutaneous

Indications

pancreatic adenocarcinoma